Bristol Myers’ Breyanzi just scored its FIFTH FDA approval—making it the only CAR T cell therapy cleared for five different cancer types. The latest win? It’s now approved for adults with relapsed or refractory marginal zone lymphoma, with a jaw-dropping 95.5% response rate in trials. One-time infusion, broad insurance coverage, and more support for patients. Cancer treatment is seriously leveling up! #Health #BodyHealth #CancerBreakthrough